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1  | INTRODUC TION
Enteric neuropathies exist as a wide range of human disorders, 
impacting variably on the gastrointestinal (GI) tract, including a 
number of severe motility disorders such as achalasia,1,2 gastropa-
resis,3,4 and slow transit constipation.5-7 Such conditions can arise 
from disruption of the development of the enteric nervous system 
(ENS) or through acquired processes, which lead to neuronal loss 
or the disturbance of specific neuronal signaling. Hirschsprung 
disease (HSCR) is one of the best characterized congenital enteric 
neuropathies, resulting from absence of ENS formation in a vari-
able region of the colon,8 which reflects a failure of the original ENS 
precursors to complete rostro- caudal colonization of the develop-
ing GI tract. The absence of the ENS in HSCR patients results in 
constriction of the terminal aganglionic intestine from unopposed 
tonic muscle contraction, causing blockage and associated disten-
tion of the proximal intestine.9 Current therapeutic intervention, 
in such cases, is limited to surgical resection of the aganglionic re-
gion. Unfortunately, in a significant proportion of HSCR patients 
such interventions have a significant morbidity10,11 and overall poor 
long- term prognosis, with patients often requiring further surgical 
management through early childhood and adolescence. Beyond 
HSCR, the failure of currently available surgical techniques to 
provide a curative treatment across a variety of motility disorders 
underlines the need for alternative approaches to treat these dev-
astating diseases.
This need, coupled with advances in our understanding of the 
underlying genetic and cellular elements involved in the develop-
ment of the ENS have provided the impetus to investigate potential 




R E V I E W  A R T I C L E
Enteric neural stem cell therapies for enteric neuropathies
C. J. McCann  | N. Thapar
Stem Cells and Regenerative Medicine, 
UCL Great Ormond Street Institute of Child 
Health, London, UK
Correspondence
C. J. McCann, Stem Cells and Regenerative 
Medicine, UCL Great Ormond Street 




Fellowship; Great Ormond Street Hospital 
Charity
Abstract
Background: Enteric neuropathies exist as a wide range of human disorders which im-
pact on gastrointestinal motility. Current standard therapies for enteric neuropathies 
are limited to surgical resection or manipulation (eg, myotomy) of affected gut segments 
or medical management including both therapy (eg, prokinetic pharmacotherapy) and 
support such as parenteral nutrition. However, such treatments often result in poor 
prognosis and significant morbidity. The current limitations in treatment options for en-
teric neuropathies underline the need for alternative approaches to treat these devas-
tating diseases. Recent advances have highlighted the potential of enteric neural stem 
cells as a possible treatment option for regenerative medicine, in such cases.
Purpose: The purpose of this review is to provide an up- to- date synopsis of the enteric 
neural stem cell research field. Here, we review in detail the initial characterization of 
enteric neural stem cells, early preclinical studies validating their use in murine models 
through to the most recent findings of therapeutic rescue of diseased gut tissue. We 
additionally pose a number of questions regarding these recent findings which will 
need to be addressed prior to clinical translation of this exciting cellular therapeutic.
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been lost via disease processes or are absent through failures in de-
velopment, in a range of GI disease models.
2  | IDENTIFIC ATION AND ISOL ATION OF 
ENTERIC NEUR AL STEM CELL S
The ENS is derived principally from a population of vagal neural 
crest- derived cells, which enter the foregut in humans at approxi-
mately embryonic week 4 (mice at approx. E9.5)12,13 and migrate in 
a rostro- caudal fashion to colonize the entire gut by approximately 
gestational week 7 in humans13 or E13.5 in mice.14	A	smaller	con-
tribution to the ENS is attributed to a sacral neural crest cell (NCC) 
population, in mouse and avian models (and presumably in humans), 
which appear to enter the terminal colon and migrate to colonize this 
terminal region in an anal- to- oral fashion.15,16
In order to fully colonize the expanding gut during embryonic 
development, vagal and sacral NCCs are required to both proliferate 
and migrate extensively. Elegant imaging studies have allowed for 
visualization of these processes17,18 demonstrating the migration of 
NCCs in chains with highly dynamic migratory patterns, including 
“trans- mesenteric” migration of enteric NCCs in the colonization 
of the mouse colon.19 This migratory pattern is highly dependent 
on several signaling pathways, which have been reviewed in detail 
elsewhere20-23 and as such are outside of the scope of this current 
review.
Of significant interest is the ability of the migratory enteric 
neural crest to colonize the expanding gut in terms of cell num-
bers. In order to enable full colonization, it is clear that a signif-
icant proliferative capacity is required to expand the relatively 
small population of pioneer neural crest cells entering the foregut 
to ultimately lead to the formation of the largest branch of the 
peripheral nervous system incorporating 200- 600 million enteric 
neurons and glia.24 This process is tightly coordinated by Ret/
GDNF signaling25 with the enteric NCCs undergoing significant 
expansion along the length of the developing gut.26.	Additionally,	
early studies by Bondurand et al. highlighted the critical role of 
SOX10 and endothelin 3 signaling in the maintenance of multi- 
lineage ENS progenitors.27 The proliferative capacity and mul-
tipotent nature of these neural crest derivatives has led to the 
investigation of enteric neural stem cells (ENSC) as a potential 
tool to treat enteric neuropathies. Interestingly, ENSCs have been 
identified in both fetal and postnatal tissues28-30 including their 
identification in human postnatal gut samples,31,32 which stimu-
lated the investigation of ENSC transplantation as a potential cell 
therapy for gut motility disorders.
Initial studies to establish the postmigratory potential of enteric 
NCCs suggested that they undergo sequential restrictions in devel-
opmental capacity.33 These investigations utilized surface marker 
expression of either the low affinity nerve growth factor receptor 
p75NTR shown to be expressed on migratory NCCs, or RET which is 
not expressed by early migratory cells34 in combination with clonal 
cell culture assays to determine the putative lineage relationships 
between migratory and postmigratory enteric NCCs. The identifica-
tion of multipotent p75+ or RET+ progenitors, which can differentiate 
toward both neural and glial lineages, in both late embryonic/fetal and 
postnatal gut tissues suggested the persistence of enteric “stem- like” 
cells after enteric neural crest migration has ended. Critically, in both 
rat and mouse gut, p75+ or RET+ progenitor cells have been shown to 
display clonal characteristics.35,36	Additionally,	after	single	cell	trans-
plantation into an organotypic gut culture system, transplanted RET+ 
cells were shown to give rise to large numbers of progeny capable 
of generating both cell lineages of the ENS.36 Similar experiments 
in an embryonic organotypic rat gut culture system suggested the 
expression of the homeodomain transcription factor Phox2b as an 
alternative or additional marker of multipotent enteric NCCs. These 
experiments crucially demonstrated the presence of early postmigra-
tory ENSCs within gut tissues and suggested the existence of “adult” 
enteric neural stem cells within mature gut, after birth.
In order to confirm the possible persistence of an ENSC pool after 
birth Bondurand et al. utilized a retrovirus- mediated gene transfer 
approach to selectively enrich and label proliferative ENSC from 
both embryonic (E11.5) and postnatal mouse tissue. Interestingly, 
both embryonic and postnatal ENS progenitor cells led to clonal 
colonies at a rate of approximately 25%. However, postnatally de-
rived ENSC were found to produce smaller colonies, suggesting a 
temporal reduction in proliferative capacity from embryogenesis to 
postnatal maturity, similar to the findings of p75+ multipotent pro-
genitors in rat gut tissue.35 Characterization of ENSC in this context 
demonstrated that clonogenic ENSCs derived from both embryonic 
and postnatal gut express SOX10. With increasing time in culture, 
these SOX10+ ENSC display expression of markers for differentiated 
enteric lineages including Tuj1+	neurons	and	GFAP+ glial cells. Hence, 
similar to in vivo enteric progenitors, isolated ENSC represent mul-
tipotent progenitors, which can self- renew before acquiring neuro-
genic or gliogenic markers prior to terminal differentiation.28
While each of these preliminary studies significantly added 
to the understanding of both the presence and behavior of ENSC 
within rodent gut, the potential translation of these studies and 
identification of ENSC within human samples was postulated to 
represent a clinically relevant source of neuronal precursors which 
could be utilized for cell replacement therapy. Similar to rodent 
gut, fetal and postnatal human gut have been shown to contain 
ENSC32,37 with their identification within samples taken from 
Key Points
•	 Autologously	derived	enteric	neural	stem	cells	(ENSC)	are	
a possible treatment option for enteric neuropathies.
• ENSC have been shown to functionally integrate and 
rescue function in animal models of intestinal disease.
• Further studies are required to fully understand the 
mechanisms of ENSC rescue before this exciting cellular 
therapy can be applied clinically.
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patients aged up to 84 years old31 suggesting that multipotent ENS 
progenitor cells are maintained throughout adult life and therefore 
could be manipulated to meet therapeutic needs. Interestingly, 
and potentially crucial in the translation of any future therapy 
was the finding that ENSC could be harvested from routine muco-
sal biopsies.32 This potentially raises the possibility of accessible 
(and repetitive) harvesting of autologous ENSC, which could be 
expanded in vitro prior to back- transplantation. Of note, whereas 
previous	rodent	studies	utilized	FACS	isolation	of	ENSC	based	on	
p75 or RET positivity, these initial human studies relied heavily on 
specific culture conditions for the enrichment of ENSC. Despite 
these studies demonstrating the presence of ENSC within human 
colon, subsequent studies have suggested that isolation methods 
based solely on culture conditions invariably include non- NCCs,38 
which brings into question this strategy as the first step of a po-
tential therapeutic option. Rather, this study found that in order 
to isolate bona fide neurospheres, comprised exclusively of neural 
crest- derived cells, antibody selection with p75+ or an alternative 
marker is crucial.
3  | TR ANSPL ANTATION OF ENTERIC 
NEUR AL STEM CELL S TO GANGLIONIC 
COLON
Although	the	archetypal	disease	model	for	neural	replacement	ther-
apies is Hirschsprung disease, where distal aganglionosis persists, 
a number of proof of principle studies have established the poten-
tial for in vivo transplantation and development of ENSC- derived 
neurons in ganglionated colonic segments within a wild- type mu-
rine context. Such investigations have typically utilized transgenic 
reporter models, under the control of enteric specific promoters to 
allow for the selective labeling and isolation of ENSC prior to culture.
Hotta et al. initially demonstrated isolation and expansion of 
ENSC from both the Ednrbkik and RetTGM mouse models in which all 
neural crest derivatives express the photoinducible protein Kikume 
or EGFP, respectively. In vivo transplantation of both embryonic 
and postnatal ENSC from these sources leads to the engraftment 
of donor- derived cells within the colonic muscularis.30 Critically, 
transplanted ENSC, in this context, have been shown to demon-
strate greater efficiency above CNS stem cells in the generation of 
enteric neurons within transplanted intestinal tissues39 and have 
been shown to differentiate to appropriate enteric phenotypes 
including neuronal and glial lineages. Interestingly, postnatally de-
rived ENSC were found to occupy a reduced area 4 weeks after 
transplantation when compared to embryonic ENSC, which may 
again reflect a temporal reduction in capacity with increasing de-
velopmental	age.	A	more	recent	study	has	suggested	that	it	may	be	
possible to exogenously enhance the behavior of ENSC with applica-
tion of various enteric growth factors. Indeed, exposure of ENSC to 
GDNF significantly increased neurosphere size, the distances over 
which neurosphere- derived cells migrate within an embryonic gut 
co- culture system or after in vivo transplantation,40 and neurogenic 
potential41 suggesting it may be possible to pharmaceutically en-
hance ENSC properties pretransplantation.
A	key	requirement	of	any	future	successful	cell	therapy	is	the	
development and integration of transplanted enteric neurons, 
which could potentially mediate motor control of intestinal seg-
ments. Initial investigations to establish the functional integration 
of transplanted ENSC demonstrated electrical activity within indi-
vidual ENSC- derived neurons from either embryonic or postnatally 
derived sources via intracellular recordings.30 Subsequent studies 
have additionally demonstrated functional integration of trans-
planted ENSC- derived neurons using a number of approaches.42,43 
Cooper et al. exclusively using postnatally derived ENSC from the 
Wnt1cre/+;R26RYFP/YFP mouse model as donors (Figure 1), where all 
NCCs and their derivatives express yellow fluorescent protein 
(YFP), similarly demonstrated successful integration and long- term 
survival of ENSC- derived neurons within wild- type ganglionated 
colon, up to 24 months posttransplantation. Using a calcium imag-
ing approach, Cooper et al. demonstrated widespread functional 
integration of multiple cells within a transplanted neural network, 
suggesting an integrated circuitry between the endogenous ENS 
and transplanted ENSC- derived neurons develops posttransplan-
tation. Crucially, these preliminary studies additionally demon-
strate that donor- derived ENSC not only form functional neurons 
in vivo but also adopt the appropriate localization and that neuro-
nal subtype specific differentiation gives rise to a repertoire of en-
teric	neurons	including	ChAT,	VAChT,	nNOS,	Calretinin,	Calbindin	
and	VIP-	expressing	neurons.30,42 Of interest, postnatally derived 
ENSC have been shown to predominantly lead to the formation 
of nNOS expressing neurons,42 whereas embryonically derived 
F IGURE  1 Characterization of Wnt1cre/+;R26RYFP/YFP- 
derived neurospheres. Representative confocal image showing 
immunohistochemistry of Wnt1cre/+;R26RYFP/YFP- derived 
neurospheres demonstrating inclusion of neurons (TuJ1) within 
labeled	neurospheres	grown	in	culture	after	YFP	FACS	isolation.	
Scale bars represent 50 μm
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ENSC have been shown to display similar excitatory and inhibitory 
neuronal lineage characteristics after transplantation.30 However, 
the mechanism for the apparent predisposition of postnatal ENSC 
to form nitrergic neurons is unclear at present.
Extending this characterization, a recent study utiliz-
ing donor ENSC under the control of an optogenetic reporter 
(Wnt1::Cre;ChR2EYFP) successfully demonstrated that ENSC- 
derived neurons from both embryonic and postnatal donors again 
form	appropriate	neuronal	 lineages	 including	ChAT	and	nNOS	ex-
pressing neurons, reflecting the 2 main branches of enteric neuro-
transmission.43 Indeed, posttransplantation optogenetic stimulation 
of donor cells in recipient colonic tissues resulted in excitatory and 
inhibitory junction potentials in colonic muscle cells further demon-
strating donor ENSC- derived neurons can mediate motor control. 
Furthermore, this study demonstrates that transplanted ENSC have 
the ability to generate the necessary circuitry for motor control with 
the development of both interneurons and motor neurons in vivo. 
Strikingly, there again appears to be disparity in the ability of embry-
onic and postnatal ENSC to form interneurons, with embryonically 
derived ENSC giving rise to both cholinergic and purinergic inter-
neurons, whereas postnatal ENSC generated purinergic neurons 
predominantly. The reasoning behind these differences is unclear at 
present, but such findings may have significant implications in the 
establishment of translational studies, whereby autologous trans-
plantation of ENSC harvested from postnatal gut, prior to expansion 
in culture and back- transplantation would be the presumptive gold 
standard therapeutic protocol.
While these preclinical murine transplantation models success-
fully demonstrate the potential for in vivo transplantation of ENSC 
and functional development of donor neurons, studies were further 
required to establish if human- derived ENSC could display simi-
lar characteristics after in vivo transplantation. Using fetal human 
ENSC isolated using p75 antibody selection and interspecies trans-
plantation into an immunedeficient (Rag2−/γc−/C5−) mouse model, 
Cooper et al. clearly demonstrated the development of human 
ENSC-	derived	 enteric	 cell	 types	 including	 neurons	 and	 glia.	 Again	
similar to earlier mouse transplants ENSC- derived cells could be 
observed within appropriate locations forming both ganglia- like 
structures and projecting fibers to make connections with the en-
dogenous ENS.29 Moreover, this study demonstrated the functional 
integration of transplanted human ENSC- derived neurons with the 
endogenous mouse ENS suggesting that the hypothesis of a poten-
tial cellular therapy for enteric neuropathies “holds water.” However, 
a critical step in proving the potential for therapeutic improvement 
of gut motility disorders relies on the demonstration of functional 
rescue of a gut pathophysiology.
4  | TR ANSPL ANTATION OF ENTERIC 
NEUR AL STEM CELL S TO DISE A SE MODEL S
In order to test the ability of ENSC to rescue a disease phenotype, 
multiple groups have used a range of recipient tissues including 
aneural gut segments, chemical ablation approaches and genetically 
altered animal models of aganglionosis or neuropathology. Initial 
experiments carried out nearly a decade ago, using what we now 
understand to be sub- optimal isolation conditions for ENSC estab-
lished that human gut- derived ENSCs could engraft within aneural-
chick gut segments cultured using chick chorioallantoic membrane 
(CAM)	or	aganglionic	gut	segments	grown	in	organotypic	culture.32 
Subsequent pilot studies using this human ENSC isolation protocol 
coupled with in vivo transplantation to chemically ablated mouse 
gut tissue suggested successful integration of PGP9.5+ neurons and 
GFAP+ glial cells indicating the presence and survival of donor cells in 
vivo.44 However, such cells did not localize within ganglia- like struc-
tures but rather appeared in isolation located in the smooth muscle 
layers suggesting failure of plexus regeneration after transplanta-
tion. Interestingly, this study also suggests that transplantation 
may	have	physiological	effects	on	gut	contractility.	A	major	caveat	
with	 chemical	 ablation	 studies	 using	 benzalkonium	 chloride	 (BAC)	
treatment is the significant limitation in clarity about the ability to 
fully ablate the entire endogenous ENS in any given gut segment. 
Additionally,	questions	remain	as	to	the	possible	invasion	of	neural	
fibers from the adjacent endogenous ENS, which may obscure the 
functional recovery provided by transplanted ENSC alone.
More recently Rollo et al. using a selective p75 enrichment ap-
proach have successfully demonstrated the isolation of human 
ENC cells from ganglionated proximal sections of resected human 
HSCR colon demonstrating the potential for autologous sourcing of 
cells from “normal” sections of patient gut in a diseased setting.45 
Interestingly, this study found that direct sorting from freshly disso-
ciated colonic segments was not an effective means of propagating 
cells. Rather cells were cultured for up to 1 week prior to isolation. 
However, this culture period was not found to lead to changes in 
neural crest gene expression, suggesting that short- term culture of 
dissociated patient samples may provide a means to overcome some 
practical hurdles related to human ENSC expansion. Moreover, this 
study demonstrated that such cells could integrate and form neu-
rons in autologous aneuronal gut explants obtained from the same 
patient critically demonstrating autologous human ENSC cell re-
placement is possible in “diseased” gut.
Additional	 studies	have	sought	 to	use	genetic	models	of	agan-
glionosis to better recapitulate the neuropathological phenotypes 
seen in enteric neuropathies. Initial studies using the EDNRBsl/sl rat 
model, which displays Hirschsprung- like aganglionosis, show that 
after intraperitoneal transplantation, p75- selected donor ENSC from 
embryonic rat intestine endogenously labeled with human placental 
alkaline phosphatase under the transcriptional control of the Rosa26 
promoter	(R26-	hPAP)	migrate	to	the	gut,	localizing	to	the	proximity	
of the submucosal and myenteric ganglia and appropriately differ-
entiate to neurons and glial cell lineages.46 Similarly, unsorted mu-
rine	ENSC	isolated	from	postnatal	Actb-	DSRed	intestine,41,47 which 
express the red fluorescent protein DSRed under the control of the 
chicken beta actin promoter, or sorted Wnt1cre/+;R26RYFP/YFP ENSC42 
transplanted to the aganglionic colon of Ednrbtm1Ywa mice, either 
in ex vivo cultures42,47 or via endoscopic microinjection,48 led to 
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colonization and engraftment of both neurons and glia. Interestingly, 
endoscopically applied ENSC were observed solely within the sub-
muscosal plexus at 1 week providing further evidence that donor 
ENSC survive within aganglionic gut segments.48
Hotta et al. have additionally shown that ENSC can be isolated from 
ganglionic segments of Ednrbtm1Ywa intestine akin to the ideal treat-
ment	option	for	HSCR	patients.	After	cell	culture,	lentiviral	labeling	and	
transplantation to the distal colon, these cells were found to retain their 
capacity for self renewal and could be observed proliferating and dif-
ferentiating into neurons within the aganglionic colon after 2 weeks in 
vivo. Indeed, the same research group has recently demonstrated that 
unsorted human ENSC harvested from postnatal ganglionated HSCR 
bowel resections can colonize both aneural chick gut and Ednrb−/− 
aganglionic colon both in ex vivo organotypic cultures and in vivo.49 
Human ENSC were observed within the gut wall, close to the site of 
transplantation and gave rise to both neurons and glia. These studies 
taken together provide further evidence for potential autologous treat-
ment of human neuropathologies. Unfortunately, due to severe pheno-
types and poor survival of aganglionic mouse lines, studies to ascertain 
functional rescue remain a rate- limiting factor.
In order to circumvent this issue, recent work from our group sought 
to utilize the neuronal nitric oxide knockout (nNOS−/−) mouse model, 
which has previously been shown to display complete loss of nNOS 
neurons in the colon resulting in slow colonic transit.50 Transplantation 
of donor ENSC, derived from postnatal Wnt1cre/+;R26RYFP/YFP mice, to 
the nNOS−/− colon leads to formation of YFP+ networks of transplanted 
cells within the distal colon (Figure 2). Despite previous transplantation 
studies, using equivalent ENSC sources, having reported quite modest 
engraftment of transplanted cells, typically colonizing approximately 
5 mm2, this study using confocal microscopy of the entire colon, 
demonstrated extensive trans- colonic engraftment of YFP+ donor 
cells up to 42 mm from the presumptive transplant site. The significant 
differences in colonization most likely reflect this differing technical 
approach rather than any changes in cellular or tissue characteristics. 
Hence, it is likely that future studies will need to assess colonization of 
target organs in a more detailed fashion at the microscopic level, rather 
than relying solely on stereoscopic live imaging techniques.
Significantly, transplantation of ENSC to nNOS−/− distal bowel 
also led to the development of nNOS+ neurons and the restoration 
of nitrergic responses. Intriguingly, such transplantation also led 
to unexpected increases in interstitial cells of Cajal (ICC) numbers 
that are reduced in the nNOS−/− colon, pointing to possible non- 
cell- autonomous effects of ENSC transplantation which had not 
previously been considered in the field. Moreover, these combined 
effects of ENSC transplantation led to the rescue of impaired colonic 
motility providing the first direct evidence that in vivo ENSC trans-
plantation can restore function, at the organ level, in a pathophysio-
logical disease model.51
5  | ALTERNATIVE CELLUL AR SOURCES 
FOR THE TRE ATMENT OF ENTERIC 
NEUROPATHIES
Together with preliminary studies of ENSC demonstrating the 
potential of an autologous stem cell therapy to rescue patho-
physiological gut deficits, alternative pluripotent cellular options 
have been similarly demonstrated to have therapeutic potential. 
A	 study	 by	 Zhou	 and	 Besner	 demonstrated	 the	 potential	 deri-
vation	of	neural	 stem	cells	 (NSC)	 from	amniotic	 fluid	 (AF)	using	
a similar culture protocol to that of ENSC. Interestingly, trans-
plantation	 of	 20,000	AF-	derived	NSC	 to	 the	 distal	 intestine	 of	
Ednrbtm1Ywa mice led to significant increases in Nestin expression 
when compared to equivalent ENSC transplants.52 Moreover, 
AF-	derived	NSC	led	to	increased	improvement	in	colonic	transit	
as assessed by bead expulsion ex vivo. Unfortunately, the poor 
survival of Ednrb−/− mice beyond approximately 4 weeks again 
precluded	the	assessment	of	functional	rescue	in	vivo.	A	poten-
tial	 limitation	 of	 the	 use	 of	 AF-	derived	 NSC	 is	 the	 reliance	 on	
culture protocols for the derivation of NSC. In this study, CD117 
was	utilized	 to	 sort	mesenchymal	 stem	cells	 from	donor	AF	via	
magnetically	activated	cell	sorting	(MACS).	Subsequently,	culture	
of this CD117 population using protocols for ENSC resulted in 
the expression of Nestin in 90% of cells, when used as a NSC 
marker.52 Previous studies have, however, demonstrated that 
Nestin may not be a specific marker for neural crest with expres-
sion shown in mesenchymal cell lineages.53,54	 Additionally,	 ex-
tensive Nestin expression has been demonstrated in non- neural 
crest- derived “neurospheres” that have been shown to contain 
mesenchymal cell types but critically lack neural crest cell types, 
including neurons and glial markers.38
As	with	many	scientific	areas	there	has	been	significant	interest	
within the ENS therapy field as to the potential of embryonic stem 
(ES) cell and induced pluripotent stem cell (iPSC) sources to generate 
ENSCs.	A	recent	study	has	demonstrated	the	derivation	of	enteric	
neural crest (ENC) from human pluripotent stem cells, including both 
F IGURE  2 Colonization and integration of transplanted ENSC 
within the colon. Representative stereoscopic image demonstrating 
that after in vivo transplantation, YFP+ transplanted cells can be 
identified within the nNOS−/− distal colon. YFP+ neurospheres 
were transplanted to the distal colon approximately 1 cm from 
the anal margin (red arrow) between P14- 17. 4 weeks after 
transplantation YFP+ (green) cells are typically observed forming 
large anastomosing networks extending along both the longitudinal 
and circumferential axes in all orientations. Scale bar represents 
500 μm
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human ES and iPSCs.55 Interestingly, thorough molecular charac-
terization of the cells demonstrates the ability to drive pluripotent 
stem cells toward an ENC fate and subsequently to terminal neu-
ronal	 subtypes	 including	nNOS,	 5-	HT,	 and	ChAT	neurons	 in	 vitro.	
This study also highlights the potential of this approach as a drug 
discovery platform. Moreover, this study demonstrates the poten-
tial rescue of a Hirschsprung phenotype with a remarkable 100% 
survival of Ednrbs−l/s−l (SSL/LEJ) mice after transplantation of up to 4 
million ENC cells to colon. Unfortunately, this study fails to provide 
a mechanism which may allow for this graft- mediated rescue. Hence, 
questions remain as to the level of aganglionosis, which is recovered 
in this strain of mice, and how transplantation of iPSC- derived ENC 
affects host colonic motility.
Li et al. similarly demonstrate derivation of neural crest stem 
cells (NCSC) from human iPSC using an alternative approach based 
around	FACS	sorting	of	HNK+, and p75+, iPSC- derived NCCs. Using 
a gut explant co- culture system to study enteric neural differen-
tiation, this study complements that of Fattahi et al. demonstrat-
ing development of a host of enteric neural markers including 
VIP,	 ChAT,	 calretinin,	 tyrosine	 hydroxylase,	 and	 nNOS	 as	 well	 as	
the functional development of electrophysiologically mature neu-
ronal phenotypes. This study also showed the ability of these 
human iPSC- derived NCSC to colonize aneural mouse and chick 
gut.	Furthermore,	engraftment	of	iPSC-	derived	NCSC	within	BAC-	
treated ganglionic and aganglionic gut tissue from human HSCR 
patients led to the development of enteric- like neurons and reduc-
tions in contractile frequency in ex vivo cultures.56 However, it is 
unclear how many iPSC- derived NCSC were transplanted in these 
conditions making any comparison difficult. One significant limita-
tion highlighted in this study was the failure of iPSC- derived NCSC 
to adopt an enteric neural phenotype in the absence of gut explants 
despite peripheral neural differentiation culture conditions. This 
caveat suggests that key microenvironmental factors may provide 
molecular cues to allow for “correct” directed differentiation of 
iPSC- derived cells, which may play an important role in translation 
of therapy where, at present, patient- specific understanding of the 
intestinal microenvironment is unfeasible.
More recently, efforts have focused on tissue engineering ap-
proaches including the development of human intestinal organoids 
(HIOs) and subsequent implantation of pluripotent- derived enteric 
NCCs (ENCC).57,58 Here, using 2 differing derivation approaches, 
the incorporation of ES or iPSC- derived enteric NCCs within HIOs 
led to the functional incorporation of neuronal and glial cell types 
within organoid units which have previously been shown to con-
tain mesenchymal cell types but lack a neural crest component. In 
both of these studies, incorporation of ENCC led to the functional 
development of albeit rudimentary activity, such as ENS- mediated 
contraction of HIOs57,58 and calcium activity within transplanted 
ENS cells derived from a human iPSC line expressing GCaMPf.58 
These studies critically provide evidence that it is possible to form 
functional intestinal units in vitro, which may play a significant role 
in drug discovery and patient specific preclinical testing of cellu-
lar and compound based strategies. Interestingly, Schlieve et al. 
additionally show that incorporation of pluripotent- derived ENCC 
led to significant alteration of numerous gastrointestinal tissue- 
specific genes. This transcriptomic alteration after supplementa-
tion of ENCC within this alternative system further supports our 
findings that transplanted ENSC can lead to non- cell- autonomous 
changes in the cellular microenvironment.51
One of the critical limitations of any cellular therapeutic treat-
ment will be the requirement to address the underlying cause of 
disease. In circumstances of disease, a mitigating factor in possible 
treatment options will be the inherent preservation of the disease 
causing mutations in autologously sourced cells. However, advances 
in gene therapy, such as CRISPR/Cas9 technology, may provide an 
elegant mechanism to correct disease- causing mutations providing a 
pool of “normal” gene- corrected ENSC or iPSC. Indeed, a recent study 
by Lai et al. elegantly demonstrated correction of HSCR- associated 
mutations in human iPSC using CRISPR/Cas9. Here, iPSC derived 
from a HSCR patient, displaying RETmutation, were corrected using 
CRISPR/Cas9. Subsequently ENCC characteristics, including neuro-
nal differentiation capability in the presence of GDNF, were restored 
after a stepwise differentiation protocol.59 Importantly, this study 
highlights the capacity to correct genetic deficiencies in potential 
donor cells using rapidly evolving gene technologies. Such an ap-
proach could theoretically be utilized to ameliorate any defective 
genetic pathways (RET, EDNRB, nNOS etc.) known to cause enteric 
neuropathy. While this exciting development opens up novel treat-
ment avenues it will be vitally important to fully understand the 
basis of disease, any potential compensatory mechanisms which may 
occur and the potential for off- target genetic effects before clinical 
application of such technologies.
6  | FUTURE CHALLENGES FOR ENTERIC 
NEUR AL STEM CELL THER APEUTIC S
Many of the challenges which will be required for translational ther-
apy of ENSC for use in the clinic, including harmonization of proto-
cols and approaches across multiple research groups and centers, 
have been outlined in a major white paper from leaders in the field.60 
Hence, this short review will focus on a number of pertinent new 
challenges, which have arisen given recent data.
Preliminary studies of murine ENSC transplantation reported 
modest engraftment and coverage of transplanted cells within host 
colon tissues. These reports, including from our laboratory, typically 
utilized stereoscopic live imaging techniques to analyze transplanted 
cell coverage of approximately 4- 11 mm2.30,42,51 Such modest cov-
erage has dogged the field, for several years, with warranted skep-
ticism of the potential to upscale cell treatment in order to facilitate 
engraftment in large regions of gut. However, our recent work has 
shown that this stereoscopic approach may be flawed. While this ap-
proach allows for initial visualization of large patches of transplanted 
cells on the serosal surface, it appears unable to adequately resolve 
(i) transplanted cells which have migrated away from the presumptive 
site of transplantation and appear in isolation/minimal numbers, (ii) 
     |  7 of 9MccANN ANd THAPAR
cells which have migrated into and along the muscularis or (iii) rel-
atively dim transplanted cell processes. Using this stereoscopic ap-
proach in our most recent study, we similarly revealed approximate 
transplanted cell coverage of 5.2 mm2. However, when whole colonic 
sections were subsequently immunolabeled with anti- GFP antibod-
ies, boosting the signal from transplanted ENSC- derived cells, we 
revealed extensive trans- colonic engraftment via confocal micros-
copy.51 Hence, despite using an identical transplantation technique 
and identical donor ENSC, previous estimations of cell coverage may 
be significantly underrepresentative of actual engraftment. This 
finding raises interesting questions regarding the migration of ENSC 
in vivo. With previous transplantation reports of cell coverage, it was 
assumed that cells migrated from the transplantation site with en-
teric neural crest characteristics, ie, in migratory chains. Our finding 
of transplanted ENSC- derived cells in the far proximal colon raises 
questions as to the migratory behavior of these cells. Figure 3 high-
lights two possible mechanisms whereby cell migration away from 
the transplant site could lead to integration of ENSC- derived cells 
at distant sites. The current dogma suggests that transplanted cells 
would initially migrate into and along the gut using cues from the 
endogenous ENS to guide transplanted cells to their eventual site of 
engraftment	(Figure	3.	upper	panel).	Alternative	studies	have	shown	
that there appears to be a close apposition of transplanted cell fibers 
with the endongenous ENS,42 supporting this theory. In this sce-
nario, the endogenous ENS is assumed to provide a “roadmap” and 
molecular cues, which transplanted ENSC could follow. We specu-
late that a possible alternative is that a proportion of transplanted 
cells may use the enteric vasculature for vessel- supported migration 
or potentially intravasate to the enteric vasculature and re- enter the 
musculature at sites along the colon where they can then respond to 
cues from the endogenous neural network as above (Figure 3 lower 
panel). Previous reports have highlighted that neural crest deriva-
tives, including neural stem cells, migrate along the vasculature in the 
CNS.61,62	Additionally,	 it	has	been	shown	that	during	development,	
migrating ENCC cross trans- mesenteric vasculature to colonize the 
colon.19 However, our current understanding of the molecular cues 
involved	in	this	process	is	limited.	A	potential	caveat	to	dispute	these	
hypotheses is that safety data post- ENSC transplantation suggests 
that donor cells are only found within the target colonic tissue42 
rather than in peripheral organs including the mesentery, which might 
be expected if a vascular migration phenomenon did exist. In order to 
progress toward possible clinical application of ENSC it will therefore 
be necessary to further investigate the exact migration pathways of 
donor ENSC in order to circumvent off- target engraftment.
More pertinent are the possible non- cell- autonomous effects, 
which transplanted ENSC may exert on the host microenvironment. 
Our recent work demonstrated that in vivo transplantation of ENSC 
into an nNOS- deficient microenvironment led to the development of 
nNOS+ neurons. Unexpectedly, we also observed significant increases 
in ICC numbers throughout the colon of these mice,51 results which 
appear consistent with observations of transcriptomic alteration after 
ENS incorporation within human intestinal organoid units.57 It is now 
clear that a much more detailed understanding of the effects that 
transplanted ENSC, be that gut or pluripotent- derived, have on the host 
neuromusculature is required. It is also apparent that our current un-
derstanding and phenotyping of gut motility disorders in terms of cellu-
lar or functional pathology is lacking, and future studies will be required 
to redress these issues in order to proceed toward clinical translation.
A	final	and	critical	challenge	for	the	field	will	be	to	replicate	
the promising findings published regarding murine ENSC trans-
plantation in the human context. Techniques used in murine 
studies have been directly translated to human samples with 
varying	results.	Although	study	of	fetal	human	samples	has	pro-
gressed to show functional integration of human cells after in 
vivo transplantation to mouse models29 transplantation studies 
using postnatal human ENSC appear to have stalled, likely due 
to issues with their expansion after antibody selection. Proof of 
concept studies do indeed show the promise for isolation and 
expansion of human ENSC from postnatal human patient sam-
ples, however, the nonselective techniques used in these stud-
ies together with our current knowledge of the heterogeneous 
composition of unsorted neurospheres38 will likely prevent any 
translation of these protocols in their current form, without sig-
nificant refinement. Realistically, for any potential treatment, 
it will be critical to demonstrate adequate enrichment of ENSC 
through antibody labeling followed by robust expansion in cul-
ture. For this to occur, alternative protocols may be required 
which diverge from previously published murine work and are 
more specifically targeted toward human stem cell culture. This 
could potentially require cross- disciplinary collaboration and 
transparent protocol exchange, within the field, to establish best 
practices in order to drive postnatal human ENSC transplanta-
tion to the forefront.
F IGURE  3 Possible ENSC migration pathways in the colon 
after transplantation. Representative schema showing possible 
migration pathways that transplanted ENSC may utilize to colonize 
the colon. Top panel: Transplanted cells initially migrate into and 
along the gut using cues from the endogenous ENS to guide them 
to	their	eventual	site	of	engraftment.	Lower	panel:	A	proportion	of	
transplanted cells may migrate via the vascular tree supported by 
blood vessel molecular cues or may potentially invade the enteric 
vasculature and subsequently re- enter the colonic musculature at 
sites along the colon
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7  | CONCLUSIONS
The past decades have seen a significant increase in our ability to 
isolate and manipulate stem cells for the treatment of enteric neu-
ropathies. Our current understanding of ENSC offers promise of a 
potential autologous cell source, which may benefit a number of dis-
ease areas. However, in order to realize this potential, future studies 
are required to ascertain transplanted cell dynamics and the effects 
of transplantation on the host microenvironment. These studies, in 
addition to improved and more efficient protocols for the isolation of 
postnatal human ENSC, are fundamental priorities before this excit-
ing cellular therapy can be translated to first- in- man studies.
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